Acromegaly - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Acromegaly - Pipeline Review, H2 2018’, provides an overview of the Acromegaly pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly

- The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects

- The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acromegaly

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

Auritec Pharmaceuticals Inc

Camurus AB

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co ...

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

Auritec Pharmaceuticals Inc

Camurus AB

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

GeneScience Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Italfarmaco SpA

leon-nanodrugs GmbH

Midatech Pharma Plc

Ono Pharmaceutical Co Ltd

Strongbridge Biopharma plc

Sun Pharma Advanced Research Company Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acromegaly – Overview

Acromegaly – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acromegaly – Overview

Acromegaly – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly – Companies Involved in Therapeutics Development

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

Auritec Pharmaceuticals Inc

Camurus AB

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

GeneScience Pharmaceuticals Co Ltd

Ionis Pharmaceuticals Inc

Italfarmaco SpA

leon-nanodrugs GmbH

Midatech Pharma Plc

Ono Pharmaceutical Co Ltd

Strongbridge Biopharma plc

Sun Pharma Advanced Research Company Ltd

Acromegaly – Drug Profiles

AP-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-GHRLRx – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITF-2984 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leon-03 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate microspheres – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide LA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-5788 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somadex – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide MR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acromegaly – Dormant Projects

Acromegaly – Discontinued Products

Acromegaly – Product Development Milestones

Featured News & Press Releases

Sep 13, 2018: Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies

Aug 31, 2018: Midatech announces interim results from proof of concept exploratory study for its MTD201 Q-Octreotide programme and Q-Sphera microsphere technology

Jul 27, 2018: Chiasma ends enrolment in MPOWERED trial for acromegaly

Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly

Jun 18, 2018: Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference

Jun 14, 2018: ATL1103/atesidorsen Early Access Program – Progress Update

Jun 14, 2018: Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

May 23, 2018: ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology

May 21, 2018: Midatech commences equivalence study in exploratory phase of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

May 14, 2018: Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial

May 10, 2018: Chiasma Reports First Quarter 2018 Results

Mar 16, 2018: Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly

Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018

Feb 28, 2018: ATL1103/atesidorsen Early Access Program - Update

Jan 30, 2018: FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals DP1038 for the Treatment of Acromegaly

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acromegaly, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Acromegaly, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Acromegaly – Pipeline by Aegis Therapeutics LLC, H2 2018

Acromegaly – Pipeline by Amryt Pharma plc, H2 2018

Acromegaly – Pipeline by Antisense Therapeutics Ltd, H2 2018

Acromegaly – Pipeline by Aquestive Therapeutics Inc, H2 2018

Acromegaly – Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Acromegaly – Pipeline by Camurus AB, H2 2018

Acromegaly – Pipeline by Chiasma Inc, H2 2018

Acromegaly – Pipeline by Crinetics Pharmaceuticals Inc, H2 2018

Acromegaly – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Acromegaly – Pipeline by Dauntless Pharmaceuticals Inc, H2 2018

Acromegaly – Pipeline by DexTech Medical AB, H2 2018

Acromegaly – Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Acromegaly – Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Acromegaly – Pipeline by Italfarmaco SpA, H2 2018

Acromegaly – Pipeline by leon-nanodrugs GmbH, H2 2018

Acromegaly – Pipeline by Midatech Pharma Plc, H2 2018

Acromegaly – Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Acromegaly – Pipeline by Strongbridge Biopharma plc, H2 2018

Acromegaly – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Acromegaly – Dormant Projects, H2 2018

Acromegaly – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Acromegaly, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Acromegaly, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports